NeuroSense Therapeutics Files 6-K Report
Ticker: NRSN · Form: 6-K · Filed: Apr 6, 2026 · CIK: 0001875091
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, press-release
TL;DR
NeuroSense Therapeutics filed a 6-K on 4/6/26 with a press release. Check for updates.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on April 6, 2026, reporting as a foreign private issuer. The filing includes a press release dated April 6, 2026, and related graphic materials. The company's mailing and business address is in Herzliya, Israel.
Why It Matters
This filing provides an update on NeuroSense Therapeutics' regulatory status and includes a press release, which may contain important business or financial information for investors.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign issuers and does not inherently indicate significant risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the 6-K report
- 0001875091 (company) — CIK number for NeuroSense Therapeutics Ltd.
- April 6, 2026 (date) — Filing date and date of the press release
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers which provides information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What documents are included in this specific 6-K filing?
This filing includes a 'REPORT OF FOREIGN PRIVATE ISSUER' (ea0285169-6k_neuro.htm), a 'PRESS RELEASE DATED APRIL 6, 2026' (ea028516901ex99-1.htm), and associated graphic materials.
Where is NeuroSense Therapeutics Ltd. based?
NeuroSense Therapeutics Ltd. has its mailing and business address at 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562, indicating it is based in Israel.
What is the CIK number for NeuroSense Therapeutics Ltd.?
The CIK number for NeuroSense Therapeutics Ltd. is 0001875091.
What is the SIC code listed for NeuroSense Therapeutics Ltd.?
The SIC code listed is 2834 for Pharmaceutical Preparations, within the Life Sciences sector.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2026-04-06 09:20:35
Filing Documents
- ea0285169-6k_neuro.htm (6-K) — 11KB
- ea028516901ex99-1.htm (EX-99.1) — 15KB
- ea028516901_ex99-1img1.jpg (GRAPHIC) — 31KB
- 0001213900-26-040185.txt ( ) — 70KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: April 6, 2026 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3